TickerTalks
Browse all tickers →
TickerTalks›$AVTR
AVAVTR

Avantor, Inc.

Hot onWhy it's trendingX mentions rising faster than the marketPrice and volume picking up
$AVTR·$7.8B·Medical - Instruments & Supplies·Healthcare
$11.44+0.8%YTD-0.7%1Y-18.3%
Mentions · last 7 days
2026-07-18: 1 posts2026-07-19: 7 posts2026-07-20: 3 posts2026-07-21: 11 posts2026-07-22: 12 posts2026-07-23: 20 posts2026-07-24: 30 posts84-69%
Price updated 2d ago·X counts updated 2d ago
AVAVTR
$AVTRAvantor, Inc.
$11.44+0.79%84 posts-69%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $AVTR, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersEvent coming upAI verdict · as of 2026-07-26

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

Avantor is down 18% over 12 months as the beaten-up life-sciences tools supplier — Q2 earnings 7/29, credit-agreement refinanced 7/17.

Avantor is a global provider of mission-critical products and services to biopharma, healthcare, education, and advanced-technologies markets — specialty chemicals, single-use processing, and lab equipment. Down 18% over 12 months but flat YTD, this is a beaten-up compounder coiled into 7/29 earnings.

The setup is a durable specialty-supplier navigating a soft biopharma cycle:

  • Revenue is flat but earnings are stable: Q1 revenue was flat YoY at $1.58B with a 32% gross margin and 7% operating margin — the last four EPS prints have been mixed but the current quarter is expected to beat per Zacks (7/22).
  • The credit-agreement refinancing is genuine capital-structure improvement: Amendment 15 (7/17) refinanced €374.2M of B-7 Euro Term Loans at EURIBOR+2.00% (down from +2.50%) — saving ~50 basis points annually is small but real balance-sheet discipline.
  • The NuSil expanded HIV-prevention partnership is a real growth vector: Population Council partnership for long-acting HIV prevention product (7/14) — that's the kind of specialty-chemicals customer expansion that supports the biopharma-tools bull thesis.

At 47% of the 52-week range and 19% above the 50-day, the tape is coiled ahead of 7/29 earnings. A revenue beat plus a biopharma-customer-demand-recovery commentary restarts the trade toward peer life-sciences-tools multiples; a soft print or a continued biopharma-spending caution comment extends the coil despite the credit-improvement moves.

What to watch: 7/29 Q2 earnings — a revenue beat plus biopharma-customer-demand-recovery commentary restarts the trade; a soft print or continued biopharma-spending caution comment extends the coil.

On the calendar: 2026-07-29 — Q2 earnings

Read the AI verdict + X sentiment for $AVTR

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Supplies specialty chemicals, lab consumables, and bioprocessing materials to pharmaceutical and life science research and manufacturing.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Instruments & Supplies sits in its cycle right now — and what that implies for $AVTR.

Medical - Instruments & Supplies · Healthcare

No material change from last week — Medline's prime vendor model wins market share as hospitals simplify sourcing, while bioprocessing component suppliers (WST, RGEN, AVTR) recover from the..

What this means for $AVTR

Partial — Supplies specialty chemicals, lab consumables, and bioprocessing materials to pharmaceutical and life science research and manufacturing; partial earnings exposure to medical - instruments & supplies demand dynamics through its product portfolio.

Industry benchmark

8-name peer basket
+9.3%YTD
+13.5%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-11.9How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-2.7%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-4.3%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
6.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
1.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-9.6%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
32.1%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026Apr 29, 2026$0.17$0.16+8.3%
Q4 2025Feb 11, 2026$0.22$0.21+4.8%
Q3 2025Oct 29, 2025$0.22$0.22-2.1%
Q2 2025Aug 1, 2025$0.24$0.25-4.0%
Next earningsWed, Jul 29·consensus EPS $0.19

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$1.6B0.0%31.7%7.3%$0.06$25.2M
Q4 FY25$1.7B-1.4%31.5%7.6%$0.08$117.2M
Q3 FY25$1.6B-5.3%32.4%-40.0%$-1.04$171.7M
Q2 FY25$1.7B-1.1%32.9%7.7%$0.09$124.8M

Forward consensus

5-year forecast · up to 13 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$6.5B$6.5B – $6.5B$0.79$0.78 – $0.8013
FY27$6.6B$6.6B – $6.7B$0.85$0.81 – $0.8913
FY28$6.8B$6.7B – $6.9B$0.93$0.81 – $1.0910
FY29$7.1B$7.0B – $7.2B$1.00$0.99 – $1.015
FY30$7.4B$7.3B – $7.4B$1.09$1.07 – $1.105

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.47%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+18.8%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+10.7%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatHigh float · 661.8M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.3% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.945-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

BuyMay 8Gregory T LucierDirector10.0K sh$83KBuyMay 1Simon DingemansDirector25.0K sh$204KBuyMar 10Sanjeev K MehraDirector125.0K sh$1.0MBuyFeb 19Gregory T LucierDirector50.0K sh$458KBuyFeb 12Gregory L SummeDirector100.0K sh$940K
+ 32 other (18 awards · 14 inkinds) in window

See when $AVTR insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KMaterial agreementJul 178-K — Item 1.01: Material agreement · Item 2.03: Material debt obligation
AI summary

Avantor completed Amendment 15 to its Credit Agreement, refinancing €374.2M of B-7 Euro Term Loans at a reduced rate of EURIBOR+2.00% (down from EURIBOR+2.50%), saving approximately 50 basis points in annual interest cost. The amended loans mature October 2032 with no change in principal amount. This liability management transaction lowers Avantor's cost of debt on its EUR-denominated leveraged loan stack.

8-KShareholder voteMay 128-K — Item 5.07: Shareholder vote
AI summary

Avantor, Inc. (AVTR) held its 2026 Annual Meeting on May 7, 2026, electing nine directors to one-year terms; notable withhold votes were cast against Louise Makin (26.6 million against vs. 593.5 million for) and Joseph Massaro (29.4 million against vs. 590.9 million for), the highest dissent in the visible excerpt, likely reflecting proxy advisor concerns on board composition or committee assignments. Other nominees including Simon Dingemans (97.5% support) and Emmanuel Ligner received broad majority support. This is a routine governance filing; elevated but minority withhold votes against two directors do not change election outcomes but may prompt board engagement with investors.

3New insider — initial holdingsMay 53
AI summary

Ludovic Brellier filed a Form 3 initial beneficial ownership statement as a newly appointed Officer of Avantor, Inc. (AVTR), with an event date of May 1, 2026, consistent with his appointment as Executive Vice President, Bioscience and Medtech Products and Chief Transformation Officer effective that date. No ownership position is detailed in the available excerpt. This is a routine officer-entry administrative filing.

8-KOfficer or director changeApr 238-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
AI summary

Avantor, Inc. (AVTR) disclosed on April 17, 2026 that Benoit Gourdier (EVP, Bioscience and Medtech Products) would transition to a supporting integration role and depart no later than December 31, 2026, and on April 23, 2026 announced the hiring of Ludovic Brellier as EVP Bioscience and Medtech Products and Chief Transformation Officer, effective May 1, 2026. Gourdier's departure and Brellier's hire represent a material leadership change in Avantor's key Bioscience segment; Brellier's additional title of Chief Transformation Officer signals an active segment integration initiative as a named strategic priority.

8-KOfficer or director changeApr 18-K — Item 5.02: Officer or director change · Item 7.01: Press release / Reg FD
8-K/AOfficer or director change (amended)Feb 258-K/A — Item 5.02: Officer or director change
8-K/AOfficer or director change (amended)Feb 258-K/A — Item 5.02: Officer or director change
8-KPress release / Reg FDFeb 118-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
+ 9 other (2 13Gs · 2 proxys · 1 SD · 1 10-Q) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Avantor, Inc. (AVTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?zacks.com·4d agoAVTR vs. ICLR: Which Stock Should Value Investors Buy Now?zacks.com·5d agoWill Avantor (AVTR) Beat Estimates Again in Its Next Earnings Report?zacks.com·11d agoAvantor Stock Up on NuSil's Expanded HIV Prevention Partnershipzacks.com·12d agoAvantor's® NuSil® Brand Expands Partnership with the Population Council to Develop Long-Acting HIV Prevention Productprnewswire.com·13d ago

More in Medical - Instruments & Supplies

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$BDX$BLFS$RGEN$WST$PLSE$MDLN$QDEL$AZTA
Voices on X · top 2 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport